World

Back to results Homes damaged in Nigeria after U.S.-backed strikes target ISIS camps

Dec 27, 2025

Washington [US], December 27: U.S.-backed airstrikes targeted Islamic State-linked camps in northwest Nigeria, with debris from the operation damaging homes in Kwara State, the Nigerian government said on Friday (December 26).
The strikes hit two ISIS camps in Sokoto's Bauni forest, targeting foreign fighters infiltrating from the Sahel region. Sixteen GPS-guided precision munitions were deployed using MQ-9 Reaper drones launched from maritime platforms in the Gulf of Guinea, according to Nigeria's information ministry.
While the government reported no civilian casualties, residents in Offa, Kwara State, described a late-night explosion that damaged multiple homes.
Quadri Saka, a resident of Offa, said he was returning home around 11 p.m. (2200GMT) when the explosion occurred. "I heard a loud sound, something hit my ear, I was disoriented and couldn't see anything," he told Reuters.
The operation, approved by Nigerian President Bola Tinubu, followed extensive intelligence gathering indicating the camps were being used by foreign ISIS elements working with local affiliates to plan large-scale attacks inside Nigeria.
Nigeria has battled Islamist insurgents for more than a decade, but the presence of foreign fighters linked to ISIS signals an escalation in the threat facing Africa's most populous nation.
Source: Fijian Broadcasting Cooperation

More news

Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial

Tampa (Florida) [US], November 2: Sirolimus-coated balloon (SCB) strategy was non-inferior to contemporary everolimus-eluting stents (EES) for Target Lesion Failure (TLF) at 12 months in patients with de novo coronary artery disease. These are the results of the TRANSFORM II randomised trial, presented today as a Late-Breaking Clinical Trial at TCT 2026 and accepted in The Lancet which confirm how MagicTouch Sirolimus Coated Balloon (Concept Medical) matches contemporary best in class stent. Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease.

Nov 02, 2026